Prosecution Insights
Last updated: November 04, 2026

Guizhou Meixinda Medical Technologies Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Guizhou Meixinda Medical Technologies Co. Ltd. currently manages a focused patent portfolio within the Biotechnology & Pharmaceuticals technology area. The presence of 1 pending office action indicates a singular active prosecution thread at this time. This matter is handled by 1 distinct examiner, which suggests that the company's current interactions with the patent office are highly centralized. Furthermore, the portfolio is restricted to 1 distinct art unit, reflecting a specific technical niche for its pending intellectual property and a lack of cross-disciplinary filings.

The busiest examiner for this portfolio is CLARKE, TRENT R, who is responsible for 1 busiest examiner pending office action. Because this examiner accounts for the 1 pending office action, the entirety of the company's current workload is under a single individual's review. For a practitioner, this concentration means that the outcome of the portfolio's active prosecution depends on the specific interpretations of this one examiner within their assigned art unit. The alignment of 1 distinct examiner with 1 distinct art unit confirms that the company is not currently navigating multiple simultaneous channels at the patent office, which simplifies the administrative burden of tracking active matters.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CLARKE, TRENT R 1 42.2% +24.7%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17905083 DEVICES AND COMPONENTS FOR AUTOMATED TISSUE PROCESSING AND STAINING AND USES THEREOF CLARKE, TRENT R 44d overdue

Top Art Units

Art UnitApps
1651 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17905083 DEVICES AND COMPONENTS FOR AUTOMATED TISSUE PROCESSING AND STAINING AND USES THEREOF CLARKE, TRENT R 1651 §103DP Final Rejection 44d overdue Pending Aug 26, 2022

Managing Guizhou Meixinda Medical Technologies Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Guizhou Meixinda Medical Technologies Co. Ltd. have?

Guizhou Meixinda Medical Technologies Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Guizhou Meixinda Medical Technologies Co. Ltd. applications?

Trent R Clarke has the most, with 1 of Guizhou Meixinda Medical Technologies Co. Ltd.'s pending office actions.

What technology area are Guizhou Meixinda Medical Technologies Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month